HIV/AIDS Treatment

Phase 2b dosing begun in monotherapy trial for 'oral entry inhibitor' HIV drug

Published in Vaccine Weekly, August 17th, 2005

Samaritan Pharmaceuticals Inc. (LIV) a developer of drugs, announced that it has commenced dosing the first patient on the phase 2 monotherapy trial of its lead "oral entry inhibitor" anti-viral agent SP01A in HIV-infected patients.

The trial is a multi-center, double-blind, randomized, placebo-controlled, study of orally administered SP01A as monotherapy treatment of HIV-infected patients.

This trial is designed to accrue treatment-experienced HIV patients that are failing on their current anti-viral therapy. Patients are entered into a 4-week wash-out phase followed by 10 days of monotherapy treatment with SP01A. The primary analysis for the study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry